Viatris Inc. (VTRS)

$11.415

+0.05

(+0.48%)▲

Live

Insights on Viatris Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 3.94B → 3.82B (in $), with an average decrease of 3.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 331.6M → -765.6M (in $), with an average decrease of 330.9% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 35.3% return, outperforming this stock by 13.5%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 44.8% return, outperforming this stock by 59.8%

Performance

  • $11.27
    $11.43
    $11.42
    downward going graph

    1.36%

    Downside

    Day's Volatility :1.4%

    Upside

    0.04%

    downward going graph
  • $8.31
    $13.49
    $11.42
    downward going graph

    27.23%

    Downside

    52 Weeks Volatility :38.4%

    Upside

    15.34%

    downward going graph

Returns

PeriodViatris Inc.Sector (Health Care)S&P500
3 Months
-3.07%
1.9%
4.1%
6 Months
24.7%
10.7%
19.4%
1 Year
21.76%
4.6%
22.6%
3 Years
-16.16%
14.2%
21.3%

Highlights

Market Capitalization
13.4B
Book Value
$17.05
Dividend Share
0.48
Dividend Yield
4.27%
Earnings Per Share (EPS)
0.05
PE Ratio
225.0
Wall Street Target Price
15.0
Profit Margin
0.35%
Operating Margin TTM
13.68%
Return On Assets TTM
2.79%
Return On Equity TTM
0.26%
Revenue TTM
15.4B
Revenue Per Share TTM
12.85
Quarterly Revenue Growth YOY
-1.0%
Gross Profit TTM
7.0B
EBITDA
4.9B
Diluted Eps TTM
0.05
Quarterly Earnings Growth YOY
-0.07
EPS Estimate Current Year
2.78
EPS Estimate Next Year
2.79
EPS Estimate Current Quarter
0.65
EPS Estimate Next Quarter
0.74

Analyst Recommendation

Hold
    13%Buy
    53%Hold
    33%Sell
Based on 15 Wall street analysts offering stock ratings for Viatris Inc.(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
2
7
7
Hold
8
8
9
Sell
5
1
1

Analyst Forecast

What analysts predicted

Upside of 31.41%

Current $11.42
Target $15.00

Company Financials

FY18Y/Y Change
Revenue
11.4B
↓ 3.98%
Net Income
352.5M
↓ 49.35%
Net Profit Margin
3.08%
↓ 2.76%
FY19Y/Y Change
Revenue
11.5B
↑ 0.58%
Net Income
16.8M
↓ 95.23%
Net Profit Margin
0.15%
↓ 2.93%
FY20Y/Y Change
Revenue
11.9B
↑ 3.87%
Net Income
-669.9M
↓ 4087.5%
Net Profit Margin
-5.61%
↓ 5.76%
FY21Y/Y Change
Revenue
17.9B
↑ 49.73%
Net Income
-1.3B
↑ 89.45%
Net Profit Margin
-7.1%
↓ 1.49%
FY22Y/Y Change
Revenue
16.3B
↓ 9.08%
Net Income
2.1B
↓ 263.79%
Net Profit Margin
12.78%
↑ 19.88%
FY23Y/Y Change
Revenue
15.4B
↓ 5.42%
Net Income
54.7M
↓ 97.37%
Net Profit Margin
0.36%
↓ 12.42%
Q3 FY22Q/Q Change
Revenue
4.1B
↓ 0.94%
Net Income
354.3M
↑ 12.87%
Net Profit Margin
8.69%
↑ 1.07%
Q4 FY22Q/Q Change
Revenue
3.9B
↓ 4.96%
Net Income
1.0B
↑ 185.41%
Net Profit Margin
26.09%
↑ 17.4%
Q1 FY23Q/Q Change
Revenue
3.7B
↓ 3.79%
Net Income
224.7M
↓ 77.78%
Net Profit Margin
6.03%
↓ 20.06%
Q2 FY23Q/Q Change
Revenue
3.9B
↑ 5.08%
Net Income
264.0M
↑ 17.49%
Net Profit Margin
6.74%
↑ 0.71%
Q3 FY23Q/Q Change
Revenue
3.9B
↑ 0.59%
Net Income
331.6M
↑ 25.61%
Net Profit Margin
8.41%
↑ 1.67%
Q4 FY23Q/Q Change
Revenue
3.8B
↓ 2.98%
Net Income
-765.6M
↓ 330.88%
Net Profit Margin
-20.02%
↓ 28.43%
FY18Y/Y Change
Total Assets
32.7B
↓ 8.58%
Total Liabilities
20.6B
↓ 8.58%
FY19Y/Y Change
Total Assets
31.3B
↓ 4.52%
Total Liabilities
19.4B
↓ 5.82%
FY20Y/Y Change
Total Assets
61.6B
↑ 96.93%
Total Liabilities
38.6B
↑ 99.25%
FY21Y/Y Change
Total Assets
54.8B
↓ 10.9%
Total Liabilities
34.4B
↓ 11.01%
FY22Y/Y Change
Total Assets
50.0B
↓ 8.79%
Total Liabilities
28.9B
↓ 15.72%
FY23Y/Y Change
Total Assets
47.7B
↓ 4.67%
Total Liabilities
27.2B
↓ 5.98%
Q3 FY22Q/Q Change
Total Assets
48.7B
↓ 4.82%
Total Liabilities
29.5B
↓ 5.87%
Q4 FY22Q/Q Change
Total Assets
50.0B
↑ 2.79%
Total Liabilities
28.9B
↓ 1.8%
Q1 FY23Q/Q Change
Total Assets
49.3B
↓ 1.46%
Total Liabilities
28.4B
↓ 2.03%
Q2 FY23Q/Q Change
Total Assets
48.7B
↓ 1.21%
Total Liabilities
27.9B
↓ 1.8%
Q3 FY23Q/Q Change
Total Assets
48.7B
↑ 0.1%
Total Liabilities
27.9B
↑ 0.09%
Q4 FY23Q/Q Change
Total Assets
47.7B
↓ 2.17%
Total Liabilities
27.2B
↓ 2.36%
FY18Y/Y Change
Operating Cash Flow
2.3B
↑ 13.41%
Investing Cash Flow
-1.2B
↑ 23.97%
Financing Cash Flow
-1.1B
↓ 42.37%
FY19Y/Y Change
Operating Cash Flow
1.8B
↓ 22.97%
Investing Cash Flow
-525.4M
↓ 56.59%
Financing Cash Flow
-1.2B
↑ 7.16%
FY20Y/Y Change
Operating Cash Flow
1.2B
↓ 31.71%
Investing Cash Flow
-301.1M
↓ 42.69%
Financing Cash Flow
-605.7M
↓ 48.19%
FY21Y/Y Change
Operating Cash Flow
3.0B
↑ 144.92%
Investing Cash Flow
-117.8M
↓ 60.88%
Financing Cash Flow
-3.0B
↑ 397.28%
FY22Y/Y Change
Operating Cash Flow
3.0B
↓ 2.13%
Investing Cash Flow
1.5B
↓ 1390.75%
Financing Cash Flow
-3.9B
↑ 28.75%
Q3 FY22Q/Q Change
Operating Cash Flow
869.0M
↑ 8.29%
Investing Cash Flow
-115.0M
↑ 40.07%
Financing Cash Flow
-758.7M
↓ 2.68%
Q4 FY22Q/Q Change
Operating Cash Flow
142.6M
↓ 83.59%
Investing Cash Flow
1.8B
↓ 1651.74%
Financing Cash Flow
-1.3B
↑ 75.38%
Q1 FY23Q/Q Change
Operating Cash Flow
971.2M
↑ 581.07%
Investing Cash Flow
-749.5M
↓ 142.0%
Financing Cash Flow
-974.7M
↓ 26.75%
Q2 FY23Q/Q Change
Operating Cash Flow
514.9M
↓ 46.98%
Investing Cash Flow
-76.6M
↓ 89.78%
Financing Cash Flow
-303.5M
↓ 68.86%
Q3 FY23Q/Q Change
Operating Cash Flow
834.1M
↑ 61.99%
Investing Cash Flow
-53.8M
↓ 29.77%
Financing Cash Flow
-97.6M
↓ 67.84%

Technicals Summary

Sell

Neutral

Buy

Viatris Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Viatris Inc.
Viatris Inc.
-3.97%
24.7%
21.76%
-16.16%
-30.48%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-0.11%
28.23%
35.27%
41.85%
77.04%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.24%
1.82%
-5.93%
13.5%
13.5%
Zoetis Inc.
Zoetis Inc.
-10.88%
-10.51%
-15.19%
-11.92%
47.93%
Catalent, Inc.
Catalent, Inc.
-0.66%
31.9%
24.68%
-51.57%
26.05%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Viatris Inc.
Viatris Inc.
225.0
225.0
NA
2.78
0.0
0.03
0.04
17.05
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
53.44
53.44
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.86
29.86
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
28.76
28.76
2.58
5.8
0.5
0.13
0.01
10.9
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Viatris Inc.
Viatris Inc.
Hold
$13.4B
-30.48%
225.0
0.35%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.3B
77.04%
53.44
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.2B
13.5%
29.86
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$66.5B
47.93%
28.76
27.43%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
26.05%
211.02
-31.77%

Institutional Holdings

  • Vanguard Group Inc

    11.98%

  • BlackRock Inc

    7.78%

  • Davis Selected Advisers

    5.28%

  • State Street Corporation

    5.21%

  • T. Rowe Price Associates, Inc.

    4.17%

  • Amvescap Plc.

    2.54%

Corporate Announcements

  • Viatris Inc. Dividends March,2024

    In the quarter ending March,2024. Viatris Inc. has declared dividend of $0.12

    Read More

Company Information

mylan is a global pharmaceutical company committed to setting new standards in healthcare. working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. we offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. in addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of hiv/aids patients in developing countries depend. we also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. learn more at mylan.com.

Organization
Viatris Inc.
Employees
38000
CEO
Mr. Scott Andrew Smith
Industry
Health Technology

Discover More

FAQs